Sub • Stance | Peptides: What Nobody Selling Or Regulating Them Will Tell You

A peptide is legal or illegal depending on a court calendar, not a toxicology report.

In September 2024 Eli Lilly sued the FDA over whether retatrutide contains 40 amino acids or 41 — a dispute worth seven extra years of market exclusivity, four extra years of protection from Medicare price negotiation, and the exclusive right to a molecule succeeding a $36.5 billion franchise. Nobody in that case argues the molecule is more dangerous one way or the other.

Eight days before I recorded this, Lilly filed six federal lawsuits against peptide sellers and disclosed it had referred more than 200 individuals and entities to regulators and licensing boards.

This episode is about how to think about that — and about what's actually in the vial, which is a separate problem with worse numbers.

Covered:

— The retatrutide classification fight and what a biologic designation actually buys

— Lilly's August 2026 lawsuits and enforcement referrals

— Why psychedelics started moving the month they became ownable

— What the FDA's 503A changes in April and July did and didn't do

— Independent testing on gray-market peptides: 41.6–71.1% failure rates, 15% endotoxin

— Why a certificate of analysis tells you almost nothing

— Where peptide knowledge actually came from (Duchaine 1981, Bhasin 1996)